cBrain A/S' (CPH:CBRAIN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

cBrain (CPH:CBRAIN) has had a great run on the share market with its stock up by a significant 46% over the last three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to study its financial indicators more closely to see if they had a hand to play in the recent price move. Particularly, we will be paying attention to cBrain's ROE today.

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

Check out our latest analysis for cBrain

Advertisement

How Do You Calculate Return On Equity?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for cBrain is:

15% = kr.16m ÷ kr.106m (Based on the trailing twelve months to December 2020).

The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every DKK1 worth of equity, the company was able to earn DKK0.15 in profit.

Why Is ROE Important For Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

A Side By Side comparison of cBrain's Earnings Growth And 15% ROE

To begin with, cBrain seems to have a respectable ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 14%. cBrain's decent returns aren't reflected in cBrain'smediocre five year net income growth average of 3.9%. So, there could be some other factors at play that could be impacting the company's growth. For instance, the company pays out a huge portion of its earnings as dividends, or is faced with competitive pressures.

Next, on comparing with the industry net income growth, we found that cBrain's reported growth was lower than the industry growth of 8.6% in the same period, which is not something we like to see.

past-earnings-growth
CPSE:CBRAIN Past Earnings Growth June 16th 2021

Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if cBrain is trading on a high P/E or a low P/E, relative to its industry.

Is cBrain Making Efficient Use Of Its Profits?

Despite having a moderate three-year median payout ratio of 30% (implying that the company retains the remaining 70% of its income), cBrain's earnings growth was quite low. So there could be some other explanation in that regard. For instance, the company's business may be deteriorating.

In addition, cBrain has been paying dividends over a period of nine years suggesting that keeping up dividend payments is way more important to the management even if it comes at the cost of business growth. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 33%. Still, forecasts suggest that cBrain's future ROE will rise to 21% even though the the company's payout ratio is not expected to change by much.

Summary

In total, it does look like cBrain has some positive aspects to its business. However, given the high ROE and high profit retention, we would expect the company to be delivering strong earnings growth, but that isn't the case here. This suggests that there might be some external threat to the business, that's hampering its growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

When trading stocks or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if cBrain might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

MI
mitchell_lawler
mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap. cover
138
PR
pri_dlp7z

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

QU
Quantanium

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About CPSE:CBRAIN

cBrain

A software company, provides software solutions for government, private, education, and non-profit sectors in Denmark, the European Union, and internationally.

High growth potential with excellent balance sheet and pays a dividend.

Advertisement

Weekly Picks

RI
Rick_Orford
FJET logo
Rick_Orford on Starfighters Space ·

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

Fair Value:US$520.6% undervalued
54 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
JO
John_Eric
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.9% undervalued
99 users have followed this narrative
2 users have commented on this narrative
15 users have liked this narrative
RC
PYPL logo
rcb9 on PayPal Holdings ·

Ten Percent More Volume, One Percent More Transaction Margin

Fair Value:US$70.8913.6% undervalued
12 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
HE
HedgeY
MU logo
HedgeY on Micron Technology ·

Micron - The Memory Bottleneck Behind the AI Supercycle

Fair Value:US$1.25k25.0% undervalued
37 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

DA
AIIO logo
david_1211213 on Robo.ai ·

Robo.ai (AIIO): A Long-Term Bullish Technical Setup

Fair Value:US$5.6449.8% undervalued
1 users have followed this narrative
7 users have commented on this narrative
1 users have liked this narrative
RO
RockeTeller
WRLG logo
RockeTeller on West Red Lake Gold Mines ·

This Junior Gold Mine Just Hit Commercial Production, 120k oz Roadmap at $7,000 Gold

Fair Value:CA$4.3681.4% undervalued
27 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
9436 logo
AstrisCorporateAdvisory on Okinawa Cellular Telephone ·

Mobile strategy pays off as churn falls

Fair Value:JP¥3.26k23.3% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
330 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9115.3% overvalued
184 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0944.0% undervalued
209 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative